Biocon Biologics honored as 2025 Asia IP Elite by IAM for 9th consecutive year
This recognition demonstrate excellence in intellectual property (IP) value creation.
This recognition demonstrate excellence in intellectual property (IP) value creation.
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Patients with BRCA mutations often face aggressive disease and poor prognosis
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
India plays a critical role in Bristol Myers Squibb’s global strategy
Subscribe To Our Newsletter & Stay Updated